After positive phase 3 data, Eli Lilly filed an NDA for orforglipron, its daily oral GLP-1 obesity pill, and secured a National Priority Review Voucher shortening FDA review to one to two months. Approval could arrive early next year, positioning the therapy to challenge weekly injectable leaders Zepbound and Wegovy.